PD-1/PD-L1 pathway: a therapeutic target in CD30+ large cell lymphomas
The programmed death-ligands, PD-L1 and PD-L2, reside on tumor cells and can bind with
programmed death-1 protein (PD-1) on T-cells, resulting in tumor immune escape. PD-1 …
programmed death-1 protein (PD-1) on T-cells, resulting in tumor immune escape. PD-1 …
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
RW Merryman, RA Redd, T Nishihori, J Chavez… - Blood …, 2021 - ashpublications.org
Autologous stem cell transplantation (ASCT) can be curative for patients with
relapsed/refractory Hodgkin lymphoma (HL). Based on studies suggesting that anti-PD-1 …
relapsed/refractory Hodgkin lymphoma (HL). Based on studies suggesting that anti-PD-1 …
Spatially resolved tumor microenvironment predicts treatment outcomes in relapsed/refractory Hodgkin lymphoma
PURPOSE About a third of patients with relapsed or refractory classic Hodgkin lymphoma
(r/r CHL) succumb to their disease after high-dose chemotherapy followed by autologous …
(r/r CHL) succumb to their disease after high-dose chemotherapy followed by autologous …
Prognostic model to predict post-autologous stem-cell transplantation outcomes in classical Hodgkin lymphoma
Purpose Our aim was to capture the biology of classical Hodgkin lymphoma (cHL) at the
time of relapse and discover novel and robust biomarkers that predict outcomes after …
time of relapse and discover novel and robust biomarkers that predict outcomes after …
Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity
ML Faber, RAA Oldham, A Thakur… - Frontiers in …, 2023 - frontiersin.org
CD30 is expressed on Hodgkin lymphomas (HL), many non-Hodgkin lymphomas (NHLs),
and non-lymphoid malignancies in children and adults. Tumor expression, combined with …
and non-lymphoid malignancies in children and adults. Tumor expression, combined with …
PD-1/PD-L1 checkpoint in hematological malignancies
O Annibali, A Crescenzi, V Tomarchio, A Pagano… - Leukemia Research, 2018 - Elsevier
Programmed cell death protein 1 (PD-1), is a cell surface receptor with an important role in
down-regulating the immune system and promoting self-tolerance by suppressing T cell …
down-regulating the immune system and promoting self-tolerance by suppressing T cell …
Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma
JM Connors, SM Ansell, M Fanale… - Blood, The Journal …, 2017 - ashpublications.org
Today, the large majority of patients with Hodgkin lymphoma are cured. 1-6 However,
treatment of patients with advanced-stage disease with optimal chemotherapy, such as …
treatment of patients with advanced-stage disease with optimal chemotherapy, such as …
Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and …
AA Moccia, F Hitz, P Hoskins, R Klasa… - Leukemia & …, 2017 - Taylor & Francis
The optimal choice of salvage therapy for patients with relapsed/refractory diffuse large B-
cell lymphoma (DLBCL) or Hodgkin lymphoma (HL) remains unknown. Based on promising …
cell lymphoma (DLBCL) or Hodgkin lymphoma (HL) remains unknown. Based on promising …
How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant
L Alinari, KA Blum - Blood, The Journal of the American Society …, 2016 - ashpublications.org
Despite the success of standard front-line chemotherapy for classical Hodgkin lymphoma
(cHL), a subset of these patients, particularly those with poor prognostic factors at diagnosis …
(cHL), a subset of these patients, particularly those with poor prognostic factors at diagnosis …